Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

PURPOSE: We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. METHODS: Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacok...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Clin Pharmacol
Main Authors: Larson, Richard A., Yin, Ophelia Q. P., Hochhaus, Andreas, Saglio, Giuseppe, Clark, Richard E., Nakamae, Hirohisa, Gallagher, Neil J., Demirhan, Eren, Hughes, Timothy P., Kantarjian, Hagop M., le Coutre, Philipp D.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5557053/
https://ncbi.nlm.nih.gov/pubmed/22207416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-011-1200-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki